The most common vegetable oil in the world is also one of the most destructive. Palm oil, a $61 billion global industry, is the reason a football field of rainforest is cleared every six seconds [C16 Biosciences]. It is also, for better or worse, the irreplaceable workhorse in thousands of consumer products, from lipstick and shampoo to ice cream and instant noodles. The problem is not the oil itself, which is cheap, stable, and versatile. The problem is the plantation.
C16 Biosciences, a New York biotech, has spent the last six years trying to brew a way out of that dilemma. In a 20,000-square-foot facility in Midtown Manhattan, they feed sugar to a proprietary strain of yeast. The microbe excretes an oil that is chemically and functionally identical to the palm-derived fats used by major brands. They call it Palmless™. The company is not trying to convince the world to stop using palm oil. It is trying to convince the world to stop growing it.
The Manhattan Fermenter
C16’s bet is a classic climate tech wedge: find a massive incumbent industry with an environmental liability, then build a drop-in replacement that solves the liability without asking the customer to change their product. Palm oil is a textbook case. It is responsible for roughly 5% of global deforestation, a significant source of greenhouse gas emissions, and a persistent supply chain risk for brands that have made public sustainability pledges [C16 Biosciences].
The company’s platform, precision fermentation, is not new. It is the same basic technology used to make insulin, rennet for cheese, and heme for Impossible Burgers. The trick is applying it to a commodity as cheap and ubiquitous as palm oil. C16’s founders,CEO Shara Ticku, COO David Heller, and CSO Harry McNamara,have focused on optimizing the yeast strain and the fermentation process to hit a cost and performance profile that can compete with the agricultural original. Their first commercial product, Torula Oil, launched in beauty formulations in 2023 [SPEEDA Edge, Jan 2024]. More importantly, they have run 50,000-liter industrial fermentation batches, a key milestone that moves the work out of the lab flask and into the realm of commercial production [SPEEDA Edge, Jan 2024].
The Beauty Wedge and the Food Frontier
C16’s initial market entry through beauty and personal care is a shrewd tactical move. The economics are more forgiving than in food, where margins are razor-thin. A high-performance oil that offers a clean, deforestation-free story is a premium ingredient a brand can market. The company says its Palmless™ oils are now trusted by leading brands in beauty, home care, and food, and have been featured in publications from The New York Times to Vogue [gopalmless.com, 2026].
The real prize, however, is the food aisle. Nearly three-quarters of all palm oil ends up in food products. To get there, C16 needs regulatory approval. The company is actively pursuing Generally Recognized As Safe (GRAS) status from the U.S. Food and Drug Administration, a necessary gate for any edible ingredient [zoonop.com, 2026]. This is a capital- and time-intensive process, but one that recent grants suggest they are well-funded to tackle.
The Backing of Patient Capital
C16 has raised over $30 million to date from a roster of investors who specialize in long-term, high-conviction bets on climate solutions [PitchBook, 2024]. Their Series A in 2020 was led by Breakthrough Energy Ventures, Bill Gates’s climate fund. In early 2024, they secured a $3.5 million grant from the Bill & Melinda Gates Foundation, followed by a $1 million venture investment from Elemental Excelerator [Crunchbase, 2024] [Green Queen, Jan 2024]. Other backers include DCVC, Waldencast, and Y Combinator, which funded the company early on.
This investor mix signals two things. First, the climate impact thesis is clear and compelling to those who measure success in tons of carbon avoided. Second, the funders understand that displacing a global agricultural commodity is a decades-long project, not a two-year sprint. The table below outlines the key funding rounds that have fueled the company’s scale-up.
| Round | Date | Amount | Lead Investor(s) |
|---|---|---|---|
| Series A | March 2020 | $20,000,000 | Breakthrough Energy Ventures |
| Grant | January 2024 | $3,500,000 | Bill & Melinda Gates Foundation |
| Venture | October 2023 | $1,000,000 | Elemental Excelerator |
Source: Compiled from SPEEDA Edge [Jan 2024], Crunchbase [2024], and Green Queen [Jan 2024].
Where the Economics Get Slippery
The ambition is vast, but the path is littered with well-funded competitors who have stumbled on the unit economics of fermentation. C16 is not alone in the race to brew palm oil. European startups like COLIPI and NoPalm Ingredients are pursuing similar microbial routes, while others like Xylome are exploring different feedstocks and organisms [SPEEDA Edge, Jan 2024].
The core challenge is cost. Palm oil is notoriously cheap, often trading below $1,000 per metric ton. Fermentation tanks, sterile nutrient feed, and downstream processing are expensive. To win, C16 must drive its production costs down through relentless strain engineering and process optimization at scale. Their 50,000-liter runs are a promising proof of scalability, but commercial viability at a million-liter scale is a different equation.
The company’s answer rests on three pillars:
- Performance parity. Their oils must function identically to palm-derived ingredients in final products, eliminating reformulation costs for brands.
- Supply chain premium. Brands may pay a modest premium for a guaranteed, deforestation-free supply that de-risks their ESG commitments.
- Regulatory moat. Successfully navigating FDA GRAS and other global food safety approvals creates a significant barrier for later entrants.
The recent Gates Foundation grant is specifically targeted at accelerating their work in food applications, suggesting confidence in the technical pathway [Crunchbase, 2024].
The Next Twelve Months
For C16, the immediate horizon is defined by regulatory milestones and commercial partnerships. Securing FDA GRAS status for one or more of its Palmless™ oils would be a watershed, unlocking the massive food and beverage market. Concurrently, announcing partnerships with major CPG brands,beyond the unnamed "leading brands" currently referenced,would provide tangible validation of both performance and demand at scale.
The math, on the back of an envelope, is stark. The world consumes about 75 million metric tons of palm oil annually. If C16’s fermentation process can eventually replace even a single percentage point of that market,750,000 tons,the climate impact would be substantial. Conservatively, that could represent over 5 million tons of CO2 equivalent avoided annually, just from prevented deforestation. The more telling figure, however, is the price. The company must beat the cost of palm oil grown on land that currently costs nothing, subsidized by ecosystems that are not on the balance sheet. Their real competitor isn’t another biotech startup. It’s a hectare of cleared rainforest in Indonesia.
Sources
- [C16 Biosciences] Company website and press materials | https://c16bio.com/
- [SPEEDA Edge, Jan 2024] Company profile and product details | https://edge.speeda.com/
- [PitchBook, 2024] Funding and company overview | https://pitchbook.com/profiles/company/232078-96
- [Crunchbase, 2024] Funding round details | https://www.crunchbase.com/organization/c16-biosciences
- [Green Queen, Jan 2024] Coverage of Elemental Excelerator investment | https://www.greenqueen.com.hk/
- [gopalmless.com, 2026] Palmless™ brand and customer claims | https://gopalmless.com
- [zoonop.com, 2026] Coverage of FDA GRAS pursuit | https://zoonop.com